A phase I/II study of the PARP inhibitor, ABT-888 plus 5-fluorouracil and oxaliplatin (modified FOLFOX-6) in patients with metastatic pancreatic cancer.Michael J. Pishvaian, Jonathan R. Brody, Rebecca Slack et al.|Journal of Clinical Oncology|2011Cited by 6
Safety profile of therapeutic pox virus-based vaccines for cancerH Kaufman, Thomas Schuetz, H. Kim Lyerly et al.|Journal of Clinical Oncology|2004Cited by 0